Although TPO-RA has shown limited efficacy to alleviate thrombocytopenia induced by conventional chemotherapy, they seem to be efficacious in the setting of HER2-targeted ADC therapy based on our small series. The gene discussed is ERBB2; the disease is Thrombocytopenia.